Cost-Effectiveness of a Technology-Enhanced Diabetes Care Management Program in Mexico

被引:6
|
作者
Gilmer, Todd [1 ]
Burgos, Jose Luis [1 ]
Cecilia Anzaldo-Campos, Maria [2 ]
Vargas-Ojeda, Adriana [3 ]
机构
[1] Univ Calif San Diego, 9500 Gilman Dr, La Jolla, CA 92093 USA
[2] Inst Mexican Seguro Social, Hosp Gen Reg 20, Tijuana, Baja California, Mexico
[3] Autonomous Univ Baja California, Tijuana, Baja California, Mexico
关键词
cost-effectiveness; diabetes; technology; BLOOD-GLUCOSE; METABOLIC-CONTROL; MEDICAL-CARE; TYPE-2; MELLITUS; MODEL; PREVALENCE; BURDEN; HEALTH; IMPACT;
D O I
10.1016/j.vhri.2018.12.006
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The prevalence of diabetes has increased substantially in Mexico over the last 40 years, leading to significant impacts on population health and the healthcare system. Technology-based solutions may improve diabetes outcomes in areas where lack of efficient transportation creates barriers to care. Objectives: To estimate the lifetime cost-effectiveness of a technology-based diabetes care management program from the perspective of the Mexican healthcare system. Methods: Clinical outcomes and cost data from a 3-arm randomized clinical trial of Dulce Wireless Tijuana, a diabetes care management program incorporating short-term mobile technology, were used as inputs in a validated simulation model for type 2 diabetes. Study arms included a control group (CG), Project Dulce diabetes care management (PD), and Project Dulce with technology enhancement (PD-TE). Results: Intervention costs were $1448 for PD and $1740 for PD-TE compared with $740 for CG. Both intervention arms increased quality-adjusted life-years and costs. The incremental cost-effectiveness ratio for PD was $1635 and for PD-TE was $2220, both compared with CG. The incremental cost-effectiveness ratio for PD-TE versus PD was $4299. The results were sensitive to the time horizon. The PE and PD-TE interventions were cost-effective under time horizons of 15 to 20 years, but were not cost-effective under time horizons of 5 to 10 years. Conclusions: Both the PD and PD-TE were highly cost-effective from a Mexican health system perspective. Considering the economic impact of the diabetes epidemic and the widespread use of cellular technology in Mexico, implementation of PD-TE is warranted.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 50 条
  • [1] Cost-Effectiveness of Pharmacist Care in Diabetes Management: A Systematic Review
    Zhu, Jiejin
    Zhou, Ying
    Wang, Gang
    DIABETES THERAPY, 2024, 15 (01) : 215 - 227
  • [2] Cost-Effectiveness of Pharmacist Care in Diabetes Management: A Systematic Review
    Jiejin Zhu
    Ying Zhou
    Gang Wang
    Diabetes Therapy, 2024, 15 : 61 - 76
  • [3] Cost-effectiveness study of depression management in Mexico
    del Carmen Lara-Munoz, Maria
    Robles-Garcia, Rebeca
    Orozco, Ricardo
    Real, Tania
    Chisholm, Dan
    Elena Medina-Mora, Ma.
    SALUD MENTAL, 2010, 33 (04) : 301 - 308
  • [4] The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program
    Neumann, Anne
    Lindholm, Lars
    Norberg, Margareta
    Schoffer, Olaf
    Klug, Stefanie J.
    Norstrom, Fredrik
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2017, 18 (07) : 905 - 919
  • [5] Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study
    Alolayan, Sultan
    Eguale, Tewodros
    Segal, Alissa R.
    Doucette, Joanne
    Rittenhouse, Brian E.
    AMERICAN JOURNAL OF LIFESTYLE MEDICINE, 2025,
  • [6] Demonstrated Cost-Effectiveness of a Telehomecare Program for Gestational Diabetes Mellitus Management
    Lemelin, Annie
    Pare, Guy
    Bernard, Sophie
    Godbout, Ariane
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (03) : 195 - 202
  • [7] Economic evaluation of a novel community-based diabetes care model in rural Mexico: a cost and cost-effectiveness study
    Duan, Kevin, I
    Rodriguez Garza, Francisco
    Flores, Hugo
    Palazuelos, Daniel
    Maza, Jimena
    Martinez-Juarez, Luis Alberto
    Elliott, Patrick F.
    Moreno Lazaro, Elena
    Enriquez Rios, Natan
    Nigenda, Gustavo
    Palazuelos, Lindsay
    McBain, Ryan K.
    BMJ OPEN, 2021, 11 (04):
  • [8] Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
    Granstrom, Ola
    Bergenheim, Klas
    McEwan, Phil
    Sennfalt, Karin
    Henriksson, Martin
    PRIMARY CARE DIABETES, 2012, 6 (02) : 127 - 136
  • [9] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Ramos, Mafalda
    Men, Peng
    Wang, Xu
    Ustyugova, Anastasia
    Lamotte, Mark
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [10] Cost-Effectiveness of a Barcelona Home Care Program for Individuals with Multimorbidity
    Vila, Anna
    Villegas, Eulalia
    Cruanyes, Jordi
    Delgado, Rosa
    Sabate, Rosa-Ana
    Ortega, Josep
    Araguas, Cristina
    Humet, Carlos
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 (05) : 1017 - 1024